Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

You may be eligible if

• Estimated glomerular filtration rate (Cockcroft-Gault method)using actual body weight of ≥ 50 mL/min at time of entry into registry
• Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)
• No history of solid organ or bone marrow transplant
• Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy within 6 months of inclusion into registry